Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $32.9 million.

  • IDEAYA Biosciences' Other Accumulated Expenses rose 72.81% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 72.81%. This contributed to the annual value of $20.0 million for FY2024, which is 86.92% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Other Accumulated Expenses stood at $32.9 million for Q3 2025, which was up 16.94% from $28.1 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Other Accumulated Expenses high stood at $32.9 million for Q3 2025, and its period low was $5.0 million during Q1 2021.
  • Its 3-year average for Other Accumulated Expenses is $17.9 million, with a median of $17.4 million in 2024.
  • As far as peak fluctuations go, IDEAYA Biosciences' Other Accumulated Expenses skyrocketed by 172.26% in 2021, and later fell by 24.41% in 2023.
  • Over the past 5 years, IDEAYA Biosciences' Other Accumulated Expenses (Quarterly) stood at $7.9 million in 2021, then spiked by 41.73% to $11.1 million in 2022, then dropped by 4.22% to $10.7 million in 2023, then surged by 86.92% to $20.0 million in 2024, then spiked by 72.81% to $32.9 million in 2025.
  • Its Other Accumulated Expenses was $32.9 million in Q3 2025, compared to $28.1 million in Q2 2025 and $26.0 million in Q1 2025.